Valuation: Chugai Pharmaceutical Co., Ltd.

Capitalization 11,526B 77.65B 66.63B 62.08B 57.76B 107B 6,688B 119B 750B 283B 3,136B 291B 285B P/E ratio 2025 *
26.4x
P/E ratio 2026 * 25.3x
Enterprise value 10,767B 72.54B 62.24B 57.99B 53.95B 99.54B 6,247B 111B 701B 264B 2,929B 272B 266B EV / Sales 2025 *
8.79x
EV / Sales 2026 * 8.39x
Free-Float
38.09%
Yield 2025 *
3.6%
Yield 2026 * 1.73%
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Chugai Pharmaceutical Co., Ltd.

1 day+1.21%
1 week+2.44%
Current month-6.92%
1 month-4.05%
3 months-15.90%
6 months+5.75%
Current year+0.07%
More quotes
1 week 6,739
Extreme 6739
7,039
1 month 6,739
Extreme 6739
7,643
Current year 6,232
Extreme 6232
8,655
1 year 5,823
Extreme 5823
8,655
3 years 3,191
Extreme 3191
8,655
5 years 3,191
Extreme 3191
8,655
10 years 1,003.33
Extreme 1003.3333
8,655
More quotes
Manager TitleAgeSince
Chief Executive Officer 62 2020-12-31
Director of Finance/CFO - 2024-03-27
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 67 1993-02-28
Director/Board Member 80 2015-02-28
Director/Board Member 76 2017-02-28
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.21%+2.44%+17.07%+89.09% 77.65B
+1.34%-2.69%-10.00%+136.58% 693B
+0.44%+4.33%+5.82%-4.65% 394B
-1.12%-1.66%+9.83%+26.39% 334B
-2.22%-5.55%-53.26%-1.90% 287B
+0.58%+0.66%-7.15%-21.43% 259B
-1.12%-4.09%-2.94%+12.40% 223B
-0.17%-1.49%-15.11%-7.23% 215B
-1.91%-4.08%-36.42%-13.43% 201B
-1.17%-0.17%-11.03%+19.18% 158B
Average -0.41%-1.33%-10.32%+23.50% 284.26B
Weighted average by Cap. -0.18%-1.55%-10.60%+36.58%
See all sector performances

Financials

2025 *2026 *
Net sales 1,225B 8.25B 7.08B 6.6B 6.14B 11.32B 711B 12.64B 79.67B 30.08B 333B 30.95B 30.3B 1,258B 8.47B 7.27B 6.77B 6.3B 11.63B 730B 12.99B 81.84B 30.89B 342B 31.79B 31.13B
Net income 436B 2.94B 2.52B 2.35B 2.18B 4.03B 253B 4.5B 28.36B 10.71B 119B 11.02B 10.79B 456B 3.07B 2.64B 2.46B 2.29B 4.22B 265B 4.71B 29.68B 11.2B 124B 11.53B 11.29B
Net Debt -759B -5.12B -4.39B -4.09B -3.8B -7.02B -441B -7.84B -49.4B -18.65B -207B -19.19B -18.79B -971B -6.55B -5.62B -5.23B -4.87B -8.98B -564B -10.03B -63.21B -23.86B -264B -24.55B -24.04B
More financial data * Estimated data
Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,026
More about the company
Date Price Change Volume
25-07-18 7,004.00 ¥ +1.21% 1,854,000
25-07-17 6,920.00 ¥ +1.76% 1,938,700
25-07-16 6,800.00 ¥ -0.72% 2,321,600
25-07-15 6,849.00 ¥ -0.51% 1,811,100
25-07-14 6,884.00 ¥ +0.69% 1,787,300

Delayed Quote Japan Exchange, July 18, 2025 at 02:30 am

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
7,004.00JPY
Average target price
8,360.71JPY
Spread / Average Target
+19.37%
Consensus

Quarterly revenue - Rate of surprise